UTHealth Houston research: semaglutide reduces severity of fatty liver disease in people with HIV

By Halle Jones, UTHealth Media Relations
March 13, 2024

Jordan E. Lake, MD, MScSemaglutide is a safe, effective therapy for a common fatty liver disease in people with HIV, according to the results of a clinical trial presented by UTHealth Houston.

The use of semaglutide 1mg weekly was safe and effective in improving metabolic dysfunction-associated steatotic liver disease (MASLD) among people living with HIV, according to clinical trial findings presented by a UTHealth Houston researcher at the Conference on Retroviruses and Opportunistic Infections in Denver, Colorado, today.

Jordan E. Lake, MD, MSc, professor of infectious diseases with McGovern Medical School at UTHealth Houston and first author of the abstract, gave an oral presentation on the study, “Semaglutide Reduces Metabolic Dysfunction-Associated Steatotic Liver Disease in People with HIV: the SLIM LIVER Study.” The study evaluated semaglutide as a treatment for MASLD among people living with HIV without diabetes.

Read the full story…